The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Richard Ramanius - Redeye AB - Analyst
: Good afternoon. Thanks for taking my questions. So I have a few. The first one, as you have a better runway now, will the readouts from TRIFOUR
and CAN10 be covered during your financial plan?
Question: Richard Ramanius - Redeye AB - Analyst
: Yeah, that's perfect. A phrase in the Q1 report caught my attention. So I wonder if you could comment on this. It says that the Board assesses that
the company has good prospects of securing future financing, for example, for a licensing deal. I don't think I've seen that wording before. So how
have your business development discussions progressed would you say since before?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 21, 2024 / 1:00PM, CANTA.ST - Q1 2024 Cantargia AB Earnings Call
Question: Richard Ramanius - Redeye AB - Analyst
: Okay. I was also wondering about what path forward you might take with CAN10, especially these interesting news in HS. And what do you think
would be the indication for the Phase 2 study?
Question: Richard Ramanius - Redeye AB - Analyst
: Great, thanks. Those were my questions.
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Hi, team. Thank you for taking my questions. I have a couple. Maybe, first, to start off with the CANFOUR trial, could you perhaps provide a bit more
color on why the start was delayed?
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Okay. That was very clear. Thank you. And maybe moving on to CAN10, is there anything that you can already advance us in terms of the Phase 2
that you plan to start next year?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 21, 2024 / 1:00PM, CANTA.ST - Q1 2024 Cantargia AB Earnings Call
And considering that -- I think you mentioned in the report that the enrollment of the psoriasis patients will start in Q3. Will we already see any
data for this patient this year or only next year?
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Okay, very clear. And maybe one final question in terms of operating expenses. How do you see this to develop throughout the rest of this year?
Will we see a further decrease as we've seen this quarter? Or do you consider that this will stabilize from now on?
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Okay, very helpful. Thank you.
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Yeah, yeah, yeah. Very helpful. Thank you. That's all for me.
| 
